查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1952811

鐮狀細胞疾病治療市場按治療類型、患者年齡層、給藥方式、疾病類型和最終用戶分類－全球預測，2026-2032年

Sickle Cell Disease Treatment Market by Treatment Type, Patient Age Group, Drug Administration Method, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鐮狀細胞疾病治療市場價值將達到 19.9 億美元，到 2026 年將成長至 21 億美元，到 2032 年將達到 31.4 億美元，年複合成長率為 6.75%。

關鍵市場統計數據
基準年 2025 19.9億美元
預計年份：2026年 21億美元
預測年份 2032 31.4億美元
複合年成長率 (%) 6.75%

一種針對現代鐮狀細胞疾病護理環境的策略方法，將臨床進展與對醫療服務提供者、支付者和製造商的實際意義聯繫起來。

鐮狀細胞疾病 (SCD) 處於血液學、遺傳學和健康差異等關鍵領域的交匯點，臨床、研究和商業相關人員需要清晰的策略洞察，才能駕馭加速發展的治療創新。本文透過整體情況目前的標準治療方案與新興治療方法，並重點闡述基因編輯、細胞療法和標靶藥物療法的進展如何改變患者的治療路徑，從而全面展現了治療格局。透過整合臨床試驗結果、監管里程碑和不斷變化的醫療服務模式，我們闡明了漸進式改善與變革性潛力之間的交集。

醫學遺傳學、監管加速和醫療保健服務領域的融合突破將如何重塑鐮狀細胞疾病的長期治療策略

隨著技術、監管和臨床因素的融合，鐮狀細胞疾病治療格局正在經歷變革性變化。基因醫學和細胞工程的進步已將基因治療平台從概念階段推進到具體的臨床項目，重新定義了緩解疾病和慢性管理。同時，藥物治療的逐步改進，包括新型製劑和最佳化的支持治療通訊協定，在許多臨床環境中提高了症狀控制率並減少了急診治療的使用。

評估美國關稅調整至 2025 年對供應鏈、製造策略和臨床准入途徑的營運和商業影響

到2025年，美國關稅政策變化的累積影響正在全球醫療保健供應鏈中造成顯著的摩擦，尤其對鐮狀細胞疾病治療所需的治療方法和輔助用品影響尤為顯著。進口生物試劑、基因和細胞療法專用生產設備以及某些輸血和血液分離術醫療設備均面臨更高的進口關稅和合規成本，迫使相關人員重新評估籌資策略和供應鏈冗餘。因此，一些製造商正在加快在國內或鄰近地區的生產投資，以降低貿易相關成本波動的風險，並確保高度複雜產品的持續供應。

根據治療方法、人群、給藥途徑、疾病亞型和醫療保健環境，制定具有高解析度細分目標市場的精準打入市場策略

有效的細分能清楚展現鐮狀細胞疾病治療方法和醫療環境的多樣性，進而為產品開發和服務提供更精準的策略。在考慮治療類型時，必須區分「輸血通訊協定」（包括用於危機管理的急性輸血和用於長期預防併發症的慢性輸血）和「骨髓移植途徑」（其中異基因移植具有根治性的潛力）。後者與自體移植（使用患者自身細胞）有所不同。按藥物治療進行細分，可以進一步區分諸如Endari等L-谷氨醯胺製劑、旨在永久性基因矯正的新興基因治療方法，以及羥基脲等已確立的藥物（羥基脲仍然是許多患者的基礎治療方法）。

區域趨勢導致美洲、歐洲、中東和非洲以及亞太地區的醫療保健生態系統在採用率、基礎設施投資和進入策略方面存在差異。

區域趨勢對鐮狀細胞疾病治療方法的採納、交付和商業化產生了顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，完善的新生兒篩檢計畫、專業的三級醫療中心和集中化的病患支援網路營造了有利於早期採用先進治療方法和進行專業臨床試驗的環境。同時，醫保報銷的討論仍圍繞著長期價值和可負擔性。而在歐洲、中東和非洲，情況則更為複雜，有些國家實現了監管協調，而有些國家則面臨基礎設施的限制。這將導致不同地區的藥物採納時間表存在差異，並需要製定針對性的市場准入策略。

由製藥公司、生物技術創新者、臨床中心和專業服務供應商組成的協作生態系統如何重塑商業化和證據生成策略

在鐮狀細胞疾病領域，各公司之間的競爭與合作行為呈現出廣泛的頻譜，涵蓋了從老牌製藥企業到小規模的生物技術公司和專業服務供應商。現有製藥公司繼續利用其強大的商業能力、現有的醫療保險支付關係和分銷網路來支持藥物和輔助治療產品的銷售。小規模的生物技術和基因療法開發商則致力於推進創新根治性，依靠與學術機構的策略夥伴關係、許可協議和臨床合作來加速研發進程並獲取特定臨床試驗族群。

為經營團隊提供切實可行的操作建議，以確保供應的確定性，使證據與支付方的需求保持一致，並加快公平獲得新的鐮狀細胞疾病治療。

行業領導者應優先考慮一系列切實可行的舉措，將科學進步轉化為可及的治療方法和永續的商業項目。首先，需要投資可擴展的生產製造和多元化的供應鏈，以確保高複雜度療法的穩定供應，同時降低貿易和關稅風險。其次，應儘早納入衛生經濟學和結果研究，使臨床開發計劃與支付方的證據要求保持一致，從而加強基於價值的合約和長期報銷。

採用嚴謹的混合方法調查方法，結合專家訪談、系統性文獻回顧和三角驗證技術，以經驗證的證據檢驗策略性結論。

本分析的調查方法結合了第一手資料和第二手資料，以確保研究的嚴謹性、透明度和可重複性。第一手資料包括對血液科醫生、移植醫生、臨床試驗研究人員、醫院採購人員和支付方代表進行結構化訪談，以收集關於臨床實踐、採購限制和證據要求的第一手觀點。此外，還舉辦了專家圓桌會議和諮詢會議，以深入了解輸血、骨髓移植和新興基因療法實施過程中面臨的營運挑戰。

整合臨床、營運和政策方面的必要因素，以製定實現鐮狀細胞疾病治療藥物持續獲益和永續商業化的路徑

總之，鐮狀細胞疾病治療的方向正從以症狀為中心的治療轉向以緩解疾病為目標的治療方法，這主要得益於基因和細胞療法、最佳化藥物治療以及支持性治療的進步。這種轉變既帶來了機遇，也帶來了責任：機會在於實現變革性的患者療效，責任在於確保公平的治療機會、維護安全監管以及建立複雜治療所需的必要基礎設施。策略上的成功取決於相關人員在臨床、商業和政策領域合作的能力，同時始終堅持以病人為中心的原則。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章鐮狀細胞貧血症治療市場（依治療方法）

  • 輸血療法
    • 急性輸血
    • 慢性輸血
  • 骨髓移植
    • 同種異體移植
    • 自體移植
  • 藥物治療
    • Endari（L-麩醯胺酸）治療
    • 基因治療
    • 羥基脲治療

第9章 依患者年齡層鐮狀細胞疾病治療市場

  • 成人版
  • 兒童

第10章 以藥物傳遞方式鐮狀細胞疾病治療市場

  • 靜脈注射
  • 口服

第11章鐮狀細胞疾病治療市場（依疾病類型分類）

  • 血紅素S-C症（HbSC）
  • 鐮狀細胞貧血症（HbSS）

第12章鐮狀細胞疾病治療市場（以最終用戶分類）

  • 診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所

第13章鐮狀細胞疾病治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章鐮狀細胞疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國鐮狀細胞疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國鐮狀細胞疾病治療市場

第17章：中國鐮狀細胞疾病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.
Product Code: MRR-B570E7E0C82D

The Sickle Cell Disease Treatment Market was valued at USD 1.99 billion in 2025 and is projected to grow to USD 2.10 billion in 2026, with a CAGR of 6.75%, reaching USD 3.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.99 billion
Estimated Year [2026] USD 2.10 billion
Forecast Year [2032] USD 3.14 billion
CAGR (%) 6.75%

A strategic orientation to the contemporary sickle cell therapeutic landscape linking clinical advances with practical implications for providers, payers, and manufacturers

Sickle cell disease (SCD) occupies a critical intersection of hematology, genetics, and health equity, and stakeholders across clinical, research, and commercial settings require clear, strategic intelligence to navigate accelerating therapeutic innovation. This introduction frames the therapeutic landscape by situating current standard-of-care practices alongside emergent modalities, highlighting how advances in gene editing, cell therapy, and targeted pharmacotherapies are reshaping patient pathways. By synthesizing clinical trial outcomes, regulatory milestones, and shifting care delivery models, the report contextualizes where incremental improvements meet transformative potential.

The intent here is to provide readers with a concise but rigorous orientation that clarifies key clinical terminologies, typical patient journeys, and the stakeholder incentives that influence adoption. Emerging therapies are discussed in relation to established interventions to help readers appreciate comparative value, safety considerations, and operational implications for administering care. This orientation sets the stage for subsequent sections by linking scientific developments to practical considerations for payers, providers, manufacturers, and patient advocates.

Transitioning from clinical foundations to strategic implications, the narrative underscores the importance of multidisciplinary coordination, capacity building in specialized centers, and supply chain resilience as essential enablers of broad access. The conclusion of this opening segment emphasizes that strategic foresight grounded in robust evidence will be crucial for stakeholders seeking to maximize patient benefit while navigating an increasingly complex commercial environment.

How converging breakthroughs in genetic medicine, regulatory acceleration, and care delivery are reshaping long-term therapeutic strategies for sickle cell disease

The sickle cell therapeutic landscape is experiencing transformative shifts driven by converging technological, regulatory, and clinical forces. Advances in genetic medicine and cell engineering have elevated gene therapy platforms from conceptual promise to tangible clinical programs, prompting a reassessment of long-term disease modification versus chronic management. Concurrently, incremental improvements in pharmacotherapy, including novel formulations and optimized supportive care protocols, are improving symptom control and reducing acute care utilization in many clinical contexts.

Regulatory pathways have adapted to accommodate accelerated development models for rare and severe conditions, which in turn affects development timelines and commercial entry strategies. Reimbursement stakeholders are increasingly focused on long-term value propositions and outcomes-based contracting, creating pressure for manufacturers to develop clear evidence-generation plans that span registries, real-world studies, and long-term follow-up. At the same time, improvements in diagnostic screening and newborn programs are influencing earlier detection and care planning, particularly in regions with established public health infrastructures.

Operationally, the rise of complex therapies has sharpened attention on manufacturing scale-up, cold-chain logistics, and specialized care delivery sites capable of performing cellular therapies or managing intensive transfusion programs. These shifts collectively reorient the landscape from episodic symptomatic care toward integrated care models that blend curative intent with sustainable chronic disease management, requiring new partnerships across clinical, commercial, and policy domains.

Assessing the operational and commercial consequences of United States tariff adjustments through 2025 on supply chains, manufacturing strategy, and clinical access pathways

The cumulative impact of tariff policy changes implemented in the United States through 2025 has introduced measurable friction across global healthcare supply chains, with specific implications for therapies and ancillary supplies used in sickle cell disease management. Imported biologic reagents, specialized manufacturing equipment for gene and cell therapies, and certain medical devices for transfusion and apheresis have been subject to elevated import duties and compliance costs, prompting stakeholders to re-evaluate sourcing strategies and supply chain redundancy. As a result, some manufacturers have accelerated onshore or nearshore manufacturing investments to mitigate exposure to trade-related cost volatility and to ensure continuity of supply for high-complexity products.

In parallel, clinical sites that rely on imported consumables for bone marrow transplant procedures and intravenous administration have encountered increased procurement lead times and higher landed costs, which in turn affect operational budgets and scheduling flexibility. Payers and health systems have responded by scrutinizing procurement contracts and by favoring vendors that demonstrate secure supply chains and localized production capabilities. Additionally, tariff-driven cost pressures have encouraged manufacturers to pursue strategic partnerships with contract manufacturing organizations and to explore technology transfer arrangements that reduce cross-border logistics complexity.

While tariffs have not uniformly shifted clinical decision-making, the downstream commercial and operational consequences are clear: stakeholders must incorporate trade policy risk into procurement planning, capital investment decisions, and pricing strategies. Those entities that proactively diversify manufacturing footprints and strengthen distributor relationships are better positioned to maintain service continuity and to protect access for patients dependent on complex therapies and supportive care.

High-resolution segmentation that aligns treatment modalities, patient demographics, administration routes, disease subtypes, and care settings to inform targeted go-to-market strategies

Meaningful segmentation reveals the heterogeneity of therapeutic approaches and care settings encountered in sickle cell disease, enabling more precise strategy development for product development and service delivery. When considering treatment types, it is essential to distinguish between blood transfusion protocols-which encompass both acute transfusion for crisis management and chronic transfusion for long-term prevention of complications-and bone marrow transplant pathways, where allogeneic transplant offers curative potential distinct from autologous approaches that leverage patient-derived cells. Pharmacotherapy segmentation further differentiates between therapies such as L-glutamine formulations like Endari, the expanding field of gene therapy modalities aiming at durable genetic correction, and long-established agents like hydroxyurea that continue to serve as backbone treatments for many patients.

Patient demographics introduce another layer of differentiation: adult and pediatric populations display distinct clinical trajectories, tolerability profiles, and care coordination needs, necessitating tailored evidence generation and dosing strategies. Administration routes are material to adoption and adherence, with intravenous therapies imposing different site-of-care requirements compared with oral regimens that enable outpatient and community-based management. Disease subtype remains a pivotal stratifier, as clinical manifestations and complication risk vary between Hemoglobin SC disease (HbSC) and sickle cell anemia (HbSS), thereby influencing therapeutic prioritization.

End-user settings provide the final axis of segmentation insight: clinics, hospitals-encompassing both private and public institutions-and research institutions each present unique operational constraints and purchasing behaviors. Together, these intersecting segmentation dimensions illuminate where clinical benefit, operational feasibility, and commercial potential converge, informing launch sequencing, pricing strategies, and stakeholder engagement plans.

Regional dynamics driving differential adoption, infrastructure investment, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems

Regional dynamics exert a strong influence on the uptake, delivery, and commercialization of sickle cell therapies, with distinctive patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established newborn screening programs, specialized tertiary centers, and concentrated patient advocacy networks create an environment where advanced therapies and specialized clinical trials can achieve early traction, while reimbursement debates continue to center on long-term value and affordability. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonization in some countries coexists with constrained infrastructure in others, leading to variable adoption timelines and a need for regionally tailored access strategies.

The Asia-Pacific region offers a mix of rapidly developing healthcare markets and mature systems that prioritize domestic capacity building for advanced biologics and cellular therapies. In many countries across Asia-Pacific, investments in manufacturing and clinical research are accelerating, but access remains shaped by differing regulatory frameworks, variable public health coverage, and localized cost sensitivities. In the Middle East and parts of Africa, the concentration of specialized centers in urban hubs can facilitate high-complexity care for select patient cohorts, yet broader access requires targeted capacity building and international collaboration.

Across all regions, cross-border partnerships, knowledge transfer, and investments in local clinical infrastructure are recurring themes. Stakeholders should calibrate regional strategies to account for differences in payer models, clinical capacity, population screening practices, and supply chain complexity to optimize patient access and commercial sustainability.

How collaborative ecosystems of pharmaceutical firms, biotech innovators, clinical centers, and specialized service providers are reshaping commercialization and evidence generation strategies

The competitive and collaborative behaviors of companies operating in the sickle cell space reflect a spectrum that ranges from legacy pharmaceutical manufacturers to small biotechnology firms and specialized service providers. Established pharmaceutical companies continue to leverage broad commercial capabilities, existing payer relationships, and distribution networks to support pharmacotherapies and supportive care products. Smaller biotech and gene therapy developers are advancing novel curative approaches, often relying on strategic partnerships, licensing agreements, and clinical collaborations with academic centers to accelerate development and to access specialized clinical trial populations.

Contract manufacturing organizations, supply chain specialists, and cell therapy service providers have become indispensable partners as companies scale complex biologic and gene-modifying products. Research institutions and hospital systems play dual roles as clinical investigators and early adopters, collaborating with industry to generate real-world evidence and to refine patient selection and care pathways. Across this ecosystem, deal activity frequently centers on technology transfer, co-development arrangements, and capacity-building investments designed to shorten time-to-patient and to secure manufacturing throughput.

From a strategic perspective, companies that invest in integrated evidence-generation programs, demonstrate supply chain resilience, and form credible partnerships with clinical networks are more likely to achieve sustainable adoption. Similarly, organizations that align commercial planning with payer evidence needs and that design pragmatic long-term follow-up studies will reduce barriers to reimbursement and accelerate patient access.

Operationally pragmatic recommendations for executives to secure supply reliability, align evidence with payer needs, and accelerate equitable access to novel sickle cell therapies

Industry leaders should prioritize a set of actionable initiatives that translate scientific progress into accessible care and sustainable commercial programs. First, invest in scalable manufacturing and diversified supply chains to mitigate trade and tariff vulnerabilities while ensuring consistent product availability for high-complexity therapies. Second, align clinical development plans with payer evidence requirements by embedding health economics and outcomes research from early phases, thereby strengthening the case for value-based contracting and long-term coverage.

Third, cultivate multi-stakeholder partnerships that bridge industry, clinical centers, and patient advocacy groups to co-design patient-centric care pathways and to expedite pragmatic trials and registries. Fourth, develop differentiated access models that account for patient age groups, administration routes, and regional infrastructure constraints, ensuring that both pediatric and adult populations receive appropriately tailored treatment options. Fifth, prepare robust launch readiness programs that include training for specialized care teams, site accreditation support, and logistics planning for intravenous and cellular therapies.

Finally, adopt modular commercial strategies that accommodate variability across disease subtypes and end-user settings, and invest in long-term safety and effectiveness surveillance to reinforce confidence among clinicians and payers. By executing on these priorities, industry leaders can reduce implementation risk, enhance patient access, and sustain commercial viability in an environment characterized by rapid innovation and evolving policy dynamics.

A rigorous mixed-methods research approach combining expert interviews, systematic literature synthesis, and triangulation techniques to underpin strategic conclusions with validated evidence

The research methodology underpinning this analysis integrates primary and secondary approaches designed to ensure rigor, transparency, and reproducibility. Primary research consisted of structured interviews with hematologists, transplant physicians, clinical trial investigators, hospital procurement leaders, and payer representatives to capture firsthand perspectives on clinical practice, procurement constraints, and evidence expectations. Complementing interviews, expert roundtables and advisory consultations provided deeper insight into operational challenges associated with administering transfusions, bone marrow transplants, and emerging gene therapies.

Secondary research involved systematic review of peer-reviewed literature, regulatory documentation, clinical trial registries, and policy publications to triangulate findings and to validate trends observed in primary interactions. Data synthesis emphasized longitudinal evidence where available, and sources were cross-referenced to identify convergent themes related to safety, efficacy, and care delivery. Analytical techniques included qualitative coding of interview transcripts, thematic mapping across segmentation axes, and scenario analysis to explore implications of supply chain and policy shifts.

Limitations of the methodology are acknowledged, including potential variability in regional data availability and the evolving nature of clinical trial outcomes for novel modalities. To mitigate these limitations, the study prioritized high-confidence sources and incorporated sensitivity checks. Quality assurance measures included independent review of analytical outputs and verification of factual statements against primary source material to maintain the integrity of conclusions.

Synthesis of clinical, operational, and policy imperatives that define the pathway to durable patient benefit and sustainable commercialization in sickle cell therapeutics

In conclusion, the trajectory of sickle cell disease treatment is moving from symptom-focused care toward approaches that offer potential disease modification, driven by advances in gene and cell therapies alongside optimized pharmacotherapy and supportive care. This shift presents both opportunities and responsibilities: opportunities to deliver transformative patient outcomes and responsibilities to ensure equitable access, maintain safety oversight, and build the infrastructure required for complex therapy delivery. Strategic success will hinge on the ability of stakeholders to coordinate across clinical, commercial, and policy domains while maintaining patient-centered priorities.

Operational resilience, including manufacturing scale-up and diversified supply chains, is a prerequisite to sustaining access in the face of trade and tariff headwinds. Equally important is the design of robust evidence-generation strategies that address payer concerns and capture long-term patient outcomes. By aligning clinical development with pragmatic implementation planning and by engaging regional stakeholders to address localized barriers, organizations can better translate innovation into meaningful improvements in population health.

Ultimately, the future of sickle cell care depends on collaborative approaches that combine scientific rigor with practical execution. Stakeholders who anticipate operational challenges, prioritize value demonstration, and commit to inclusive access models will be best positioned to deliver durable benefits to patients while achieving commercial and clinical objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sickle Cell Disease Treatment Market, by Treatment Type

  • 8.1. Blood Transfusion
    • 8.1.1. Acute Transfusion
    • 8.1.2. Chronic Transfusion
  • 8.2. Bone Marrow Transplant
    • 8.2.1. Allogeneic Transplant
    • 8.2.2. Autologous Transplant
  • 8.3. Pharmacotherapy
    • 8.3.1. Endari (L-Glutamine) Treatment
    • 8.3.2. Gene Therapy
    • 8.3.3. Hydroxyurea Treatment

9. Sickle Cell Disease Treatment Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Pediatric

10. Sickle Cell Disease Treatment Market, by Drug Administration Method

  • 10.1. Intravenous
  • 10.2. Oral

11. Sickle Cell Disease Treatment Market, by Disease Type

  • 11.1. Hemoglobin SC Disease (HbSC)
  • 11.2. Sickle Cell Anemia (HbSS)

12. Sickle Cell Disease Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Research Institutions

13. Sickle Cell Disease Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sickle Cell Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sickle Cell Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sickle Cell Disease Treatment Market

17. China Sickle Cell Disease Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Akums Drugs and Pharmaceuticals Ltd.
  • 18.6. Beam Therapeutics, Inc.
  • 18.7. Biogen Inc.
  • 18.8. Bluebird Bio, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CRISPR Therapeutics AG
  • 18.11. Editas Medicine, Inc.
  • 18.12. Emmaus Medical, Inc.
  • 18.13. F. Hoffmann-La Roche AG
  • 18.14. GlycoMimetics, Inc.
  • 18.15. Intellia Therapeutics, Inc.
  • 18.16. Medunik USA
  • 18.17. Novartis AG
  • 18.18. Protagonist Therapeutics, Inc.
  • 18.19. Sangamo Therapeutics, Inc.
  • 18.20. Sanofi S.A.
  • 18.21. Vertex Pharmaceuticals, Inc.
  • 18.22. Vor Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 200. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)